67469-02-7

Usage

Uses

Used in Pharmaceutical Industry:
1,2-Benzenediamine, 4-(methylthio)is used as an intermediate in the synthesis of metabolites for the pharmaceutical compound Albendazole (A511610). Albendazole is a widely used anthelmintic drug, effective against various parasitic worm infections. 1,2-Benzenediamine, 4-(methylthio)plays a crucial role in the production process, contributing to the development of this essential medication.

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 31431-10-4 2-amino-4-methylthio-1-nitrobenzene 

Downstream Products

• 121537-61-9 6-(methylthio)-1H-benzimidazole 
• 960000-77-5 methyl 5-(5-(methylthio)-1H-benzimidazol-1-yl)-3-((phenylmethyl)oxy)-2-thiophenecarboxylate 
• 960000-79-7 methyl 5-(5-(methylsulfonyl)-1H-benzimidazol-1-yl)-3-((phenylmethyl)oxy)-2-thiophenecarboxylate 
• 1192251-76-5 2-(2'-fluorobiphenyl-4-yl)-6-(methylsulfinyl)-1H-benzimidazole 
• 1192251-75-4 2-(2'-fluorobiphenyl-4-yl)-6-(methylsulfanyl)-1H-benzimidazole 
• 102590-97-6 2,3-bis-(4-methoxy-phenyl)-6-methylsulfanyl-quinoxaline 

Relevant academic research and scientific papers

NOVEL SUBSTITUTED HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Substituted heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic Syndrome; neurological disease; cancer; and liver steatosis. Formula (I).

Benzimidazole Thiophene Compounds

The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

BENZIMIDAZOLE THIOPHENE COMPOUNDS

The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.